+
Our goal at Brahm Life Sciences is to bridge ancient wisdom and modern biotechnology, advancing human longevity and vitality through sustainable innovation. By uniting global science and India’s life sciences ecosystem — accelerating breakthroughs in regenerative medicine, cellular health, and āyurvedic innovation for a healthier, longer-lived world.
Despite India’s deep heritage in healing and its growing scientific talent, the country remains underconnected to the global biotechnology and longevity ecosystem. Frontier research often struggles to find scalable markets, while India’s biomedical infrastructure remains fragmented between tradition and modernity. Brahm Life Sciences bridges this divide — creating a platform where ancient insights meet cutting-edge science, where global innovators collaborate with Indian researchers, and where the future of human longevity is built on the wisdom of āyus.
Brahm Life Sciences brings together a global network of scientists, entrepreneurs, and investors operating across biotechnology, regenerative medicine, and longevity innovation. Our expertise spans cellular and metabolic health, biomaterials, AI-driven diagnostics, āyurgenomics, nutrigenomics, and Āyurvedic translational research — connecting the precision of modern science with the holistic intelligence of ancient systems.
Operations in India and partnerships across Europe, the Middle East, and Asia-Pacific, we combine world-class research with India’s unmatched scale, manufacturing capabilities, and scientific talent. This convergence allows Brahm Life Sciences to accelerate innovation from lab to market — turning pioneering ideas into accessible solutions that redefine how humanity approaches health, vitality, and lifespan.
At the heart of Brahm Life Sciences lies a conviction that longevity is the next great frontier of human progress. Through its partnership with Iduna Capital — a global venture fund focused on the biology of aging — Brahm invests in breakthrough technologies that extend both lifespan and healthspan by targeting the root causes of aging itself.
Backed by a world-class network of scientists, clinicians, and venture leaders, Iduna Capital identifies and supports early-stage biotech innovators developing cellular rejuvenation therapies, immune-system enhancements, regenerative biomaterials, and metabolic optimization technologies.
With a projected $50M fund size, the partnership between Brahm and Iduna creates a full-spectrum platform — from research and venture financing to regulatory navigation and market access — bridging the world’s most advanced longevity science with India’s scale, infrastructure, and talent.
Together, Brahm Life Sciences and Iduna Capital aim to transform aging from inevitability to optionality —
Iduna Capital is a global venture capital fund focused on investing in breakthrough technologies that target the root causes of aging. Backed by a world-class team of scientists, doctors, and venture leaders, Iduna identifies and supports early-stage longevity biotech companies working on solutions to extend both lifespan and healthspan. The fund’s strategy centers on regulated therapies and bold moonshot ideas — ranging from cellular rejuvenation to immune system enhancements — aiming to deliver population-wide, scalable health benefits. With a projected $10M fund size and a mission to transform aging from inevitability to optionality, Iduna Capital is at the forefront of the longevity revolution.
For centuries, aging was accepted as an unstoppable decline — but today, science is rewriting that narrative. We now understand that aging is not just a matter of time, but a biological process — one we can measure, modulate, and eventually reverse. By targeting the underlying drivers of aging — such as inflammation, cellular senescence, DNA damage, mitochondrial dysfunction, and stem cell exhaustion — we can extend healthspan, not just lifespan. This means more years lived in good health, free from chronic illness, cognitive decline, and frailty. With emerging tools like AI-driven drug discovery, gene editing (CRISPR), cellular reprogramming, and precision diagnostics, we have the opportunity to not only delay aging, but to treat it as a condition in itself.
Beiersdorf and Vincere Biosciences Partner to Bring Mitophagy to Market.
Why Lifespan Heritability Is Twice as High as We Thought
Billions of lab-grown mitochondria, real-world regeneration, & a vision for future medicine.
-Peter Højer Mathiesen
Director of Life Sciences, Brahm
© 2025 Brahm. All rights reserved.
Brahm is a registered entity. All content, visuals, and materials are protected by applicable intellectual property laws.